Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
that´s nice again
complete report : 4000$
Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Feb. 16, 2012 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 http://www.reportlinker.com/p0704129/Graft-Versus-Host-Disease-GVHD-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategoryGraft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, "Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Graft Versus Host Disease (GVHD) Therapeutics market. The report identifies the key trends shaping and driving the global Graft Versus Host Disease (GVHD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Graft Versus Host Disease (GVHD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Graft Versus Host Disease (GVHD) Therapeutics market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Graft Versus Host Disease (GVHD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Graft Versus Host Disease (GVHD) Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Graft Versus Host Disease (GVHD) Therapeutics market.- Analysis of key recent licensing and partnership agreements in Graft Versus Host Disease (GVHD) Therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Graft Versus Host Disease (GVHD) Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Graft Versus Host Disease (GVHD) Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global Graft Versus Host Disease (GVHD) Therapeutics market landscape? - Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 52 Introduction 62.1 Overview 62.1.1 Classification of GVHD 62.2 Epidemiology 82.3 Etiology 92.4 Signs and Symptoms 102.4.1 Acute GVHD 112.4.2 Chronic GVHD 112.5 Diagnosis 132.5.1 Laboratory Tests 132.5.2 Imaging Tests 132.5.3 Biopsies 132.5.4 Other Tests and Procedures 132.6 Prophylaxis 142.7 Treatment 142.7.1 Primary or First-Line Therapy for aGVHD 142.7.2 Secondary or Second-Line Therapy for aGVHD 152.7.3 Primary or First-Line Therapy for cGVHD 152.7.4 Secondary or Second-Line Therapy for cGVHD 152.7.5 Supportive Care 152.8 GlobalData Pipeline Report Guidance 163 GVHD Therapeutics - Market Characterization 173.1 Major Markets, Market Size (2005-2010) 173.2 Major Markets, Market Forecast (2010-2018) 193.3 US Market Size (2005-2010) 213.4 The US Market Forecast (2010-2018) 223.5 The UK Market Size (2005-2010) 233.6 The UK Market Forecast (2010-2018) 243.7 Germany Market Size (2005-2010) 253.8 Germany Market Forecast (2010-2018) 263.9 Italy Market Size (2005-2010) 273.10 Italy Market Forecast (2010-2018) 283.11 France Market Size (2005-2010) 293.12 France Market Forecast (2010-2018) 303.13 Spain Market Size (2005-2010) 313.14 Spain Market Forecast (2010-2018) 323.15 Japan Market Size (2005-2010) 333.16 Japan Market Forecast (2010-2018) 343.17 Drivers and Barriers for GVHD Therapeutic Market 353.17.1 Drivers for GVHD Market 353.17.2 Barriers for GVHD Market 353.18 Opportunity and Unmet Need 363.19 Key Takeaway 364 GVHD Therapeutics Market - Competitive Assessment 374.1 Overview 374.1.1 Strategic Competitor Assessment 374.2 GVHD Market Marketed Products Profile 384.2.1 Corticosteroids 384.2.2 Cyclosporine 384.2.3 Antithymocyte Globulin (ATG) (equine/rabbit) 394.2.4 Mycophenolate Mofetil (MMF) 404.2.5 Tacrolimus 404.3 Key Takeaway 415 GVHD - Pipeline Assessment 425.1 Overview 425.2 Strategic Pipeline Assessment 425.3 GVHD Pipeline Analysis - Pipeline by Clinical Phases of Development 435.3.1 GVHD Therapeutics - Phase III Clinical Pipeline 435.3.2 GVHD Therapeutics - Phase II Clinical Pipeline 445.3.3 GVHD Therapeutics - Phase I/II Clinical Pipeline 445.3.4 GVHD Therapeutics - Phase I Clinical Pipeline 445.3.5 GVHD Therapeutics - Preclinical Pipeline 455.4 GVHD Pipeline by Mechanism of Action 455.5 GVHD Technology Trends Analytical Framework 475.6 GVHD Therapeutics - Promising Drugs under Clinical Development 485.7 Molecule Profile for Promising Drugs under Clinical Development 495.7.1 ATIR (ANX-530) 495.7.2 Budesonide 495.7.3 Leukotac (inolimomab) 505.7.4 OrBec (Beclomethasone Dipropionate, Oral BDP, Oral Beclomethasone Dipropionate) 505.7.5 Prochymal 515.8 Key Takeaway 526 GVHD Therapeutics - Clinical Trials Mapping 536.1 Overview 536.2 Clinical Trials Mapping by Region/Country 536.3 Clinical Trials Mapping by Phase 546.4 Clinical Trials Mapping by Trial Status 556.5 Clinical Trials Mapping by Overall Sponsors 566.6 Clinical Trials Mapping by Prominent Sponsors 576.7 Participants in Therapeutic Clinical Trials - Companies 587 GVHD Therapeutics - Implications for Future Competition 597.1 Future Market Competition Scenario 598 Global GVHD Therapeutics - Future Players 608.1 Introduction 608.2 Dr. Falk Pharma GmbH 608.2.1 Company Overview 608.3 EUSA Pharma, Inc. 618.3.1 Company Overview 618.4 Kiadis Pharma B.V. 618.4.1 Company Overview 618.5 Osiris Therapeutics, Inc. 628.5.1 Company Overview 628.5.2 Business Overview 628.6 Soligenix, Inc. 638.6.1 Company Overview 638.6.2 Business Overview 639 Licensing and Partnership Deals 6510 Global Graft Versus Host Disease Therapeutics - Appendix 6710.1 Definitions 6710.2 Acronyms 6710.3 Methodology 6910.3.1 Coverage 6910.3.2 Secondary Research 6910.3.3 Forecasting 7010.3.4 Primary Research 7210.3.5 Expert Panel Validation 7310.4 Contact Us 7310.5 Disclaimer 7310.6 Sources 731.1 List of TablesTable 1: Clinical Staging and Grading of aGVHD 7Table 2: Clinicopathologic Classification of cGVHD 7Table 3: Incidence of GVHD, 2010 8Table 4: Signs and Symptoms of aGVHD and cGVHD 10Table 5: GVHD Therapeutics, Global, Market Revenue ($m), 2005-2010 17Table 6: GVHD Therapeutics, Global, Revenue Forecasts ($m), 2010-2018 19Table 7: GVHD Therapeutics, The US, Market Historical Revenue ($m), 2005-2010 21Table 8: GVHD Therapeutics, The US, Historical Revenue Forecasts ($m), 2010-2018 22Table 9: GVHD Therapeutics, The UK, Market Historical Revenue ($m), 2005-2010 23Table 10: GVHD Therapeutics, The UK, Revenue Forecasts ($m), 2010-2018 24Table 11: GVHD Therapeutics, Germany, Market Revenue ($m), 2005-2010 25Table 12: GVHD Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018 26Table 13: GVHD Therapeutics, Italy, Market Revenue ($m), 2005-2010 27Table 14: GVHD Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018 28Table 15: GVHD Therapeutics, France, Market Revenue ($m), 2005-2010 29Table 16: GVHD Therapeutics, France, Revenue Forecasts ($m), 2010-2018 30Table 17: GVHD Therapeutics, Spain, Market Revenue ($m), 2005-2010 31Table 18: GVHD Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018 32Table 19: GVHD Therapeutics, Japan, Market Revenue ($m), 2005-2010 33Table 20: GVHD Therapeutics, Japan, Revenue Forecasts ($m), 2010-2018 34Table 21: GVHD Therapeutics - Phase III Clinical Pipeline, 2011 43Table 22: GVHD Therapeutics - Phase II Clinical Pipeline, 2011 44Table 23: GVHD Therapeutics - Phase I/II Clinical Pipeline, 2011 44Table 24: GVHD Therapeutics - Phase I Clinical Pipeline, 2011 44Table 25: GVHD Therapeutics - Preclinical Pipeline, 2011 45Table 26: Mechanism of Action Constituting Classes in Figure 28 46Table 27: GVHD Therapeutics - Promising Drugs Under Clinical Development, 2011 48Table 28: GVHD Clinical Trials by Region - Number, 2011 53Table 29: GVHD Clinical Trials by Phase, 2011 54Table 30: GVHD Clinical Trials by Status, 2011 55Table 31: GVHD Clinical Trials by Overall Sponsors, 2011 56Table 32: GVHD Clinical Trials by Prominent Sponsors, 2011 57Table 33: GVHD Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 58Table 34: Dr. Falk Pharma GmbH- GVHD Therapeutics Pipeline 60Table 35: EUSA Pharma, Inc. - GVHD Therapeutics Pipeline 61Table 36: Kiadis Pharma B.V. - GVHD Therapeutics Pipeline 61Table 37: Osiris Therapeutics, Inc.- GVHD Therapeutics Pipeline 63Table 38: Soligenix, Inc. - GVHD Therapeutics Pipeline 64Table 39: GVHD Therapeutics, Licensing and Partnership Deals 651.2 List of FiguresFigure 1: Stages of GVHD after Allogeneic HCT 9Figure 2: Mechanisms of Injury by Tissue-Infiltrating Alloreactive T-Cells 10Figure 3: Skin Affected by GVHD (Stage 3) 12Figure 4: Oral Mucosal Changes in Patients with cGVHD 12Figure 5: GVHD Therapeutics, Global, Market Revenue ($m), 2005-2010 17Figure 6: GVHD Therapeutics, Market Share ($m, %), 2010 18Figure 7: GVHD Therapeutics, Global, Revenue Forecasts ($m), 2010-2018 19Figure 8: GVHD Therapeutics, Forecast Market Share ($m, %), 2018 20Figure 9: GVHD Therapeutics, The US, Market Revenue ($m), 2005-2010 21Figure 10: GVHD Therapeutics, The US, Revenue Forecasts ($m), 2010-2018 22Figure 11: GVHD Therapeutics, The UK, Market Revenue ($m), 2005-2010 23Figure 12: GVHD Therapeutics, The UK, Revenue Forecasts ($m), 2010-2018 24Figure 13: GVHD Therapeutics, Germany, Market Revenue ($m), 2005-2010 25Figure 14: GVHD Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018 26Figure 15: GVHD Therapeutics, Italy, Market Revenue ($m), 2005-2010 27Figure 16: GVHD Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018 28Figure 17: GVHD Therapeutics, France, Market Revenue ($m), 2005-2010 29Figure 18: GVHD Therapeutics, France, Revenue Forecasts ($m), 2010-2018 30Figure 19: GVHD Therapeutics, Spain, Market Revenue ($m), 2005-2010 31Figure 20: GVHD Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018 32Figure 21: GVHD Therapeutics, Japan, Market Revenue ($m), 2005-2010 33Figure 22: GVHD Therapeutics, Japan, Revenue Forecasts ($m), 2010-2018 34Figure 23: GVHD Therapeutic Market - Drivers and Barriers 35Figure 24: Opportunity and Unmet Need in the GVHD Therapeutic Market 36Figure 25: Strategic Competitor Assessment of Marketed Products for GVHD, 2010 37Figure 26: Pipeline Products by Phase of Clinical Development, 2011 42Figure 27: GVHD Therapeutics Pipeline by Phase of Clinical Development, 2011 43Figure 28: GVHD Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 45Figure 29: Technology Trends Analytical Framework of GVHD Pipeline, 2011 47Figure 30: Technology Trends Analytical Framework of GVHD Pipeline - Description, 2011 48Figure 31: GVHD Clinical Trials by Region, 2011 53Figure 32: GVHD Clinical Trials by Phase, 2011 54Figure 33: GVHD Clinical Trials by Status, 2011 55Figure 34: GVHD Clinical Trials by Sponsors, 2011 56Figure 35: GVHD Clinical Trials by Prominent Sponsors, 2011 57Figure 36: GVHD Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 58Figure 37: Implications for Future Market Competition in the GVHD Market, 2011 59Figure 38: GVHD Therapeutics, Clinical Pipeline by Company, 2011 60Figure 39: GlobalData Market Forecasting Model 72Companies mentionedDr. Falk Pharma GmbHEUSA Pharma, Inc.Kiadis Pharma B.V.Osiris Therapeutics, Inc.Soligenix, Inc.To order this report:: Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018More Market Research ReportCheck our Industry Analysis and Insights
Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Copyright (C) 2012 PR Newswire. All rights reserved
38: Soligenix, Inc. - GVHD Therapeutics Pipeline 64Table
maybe
5 days left
0 money = 0 shares
what a s... 0,56
it can be
absolutely properly
this leads to the assertion
Soligenix = strong BUY
congratulations
i can´t double (not enough money) but +35%
catch you the cheap shares there still now. they are the next week snow from yesterday
NEWS AGAIN
my friends
it looks good for us
we have enough good news for 1-2$
wait and see the $$$ is coming
you think it goes down?
i´m with you
let rod work
thats good
from yahoo finance:
SOLIGENIX, INC. (SNGXD.OB) -OTC BB
0.79 0.01(1.39%) Feb 3, 3:56PM EST
Add to Portfolio
Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Sep 30, 2011 Jun 30, 2011 Mar 31, 2011 Dec 31, 2010
Total Revenue 5,796 406 808 307
Cost of Revenue 655 350 554 236
Gross Profit 5,141 56 254 71
Operating Expenses
Research Development 2,666 1,307 1,256 1,659
Selling General and Administrative 272 682 721 835
Non Recurring - - - -
Others - - - -
Total Operating Expenses - - - -
Operating Income or Loss 2,203 (1,933) (1,723) (2,423)
Income from Continuing Operations
Total Other Income/Expenses Net - - 2 -
Earnings Before Interest And Taxes 2,205 (1,931) (1,720) (2,184)
Interest Expense - - - 1
Income Before Tax 2,205 (1,931) (1,720) (2,185)
Income Tax Expense - - - -
Minority Interest - - - -
Net Income From Continuing Ops 2,205 (1,931) (1,720) (1,939)
Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -
Net Income 2,205 (1,931) (1,720) (1,939)
Preferred Stock And Other Adjustments - - - -
Net Income Applicable To Common Shares 2,205 (1,931) (1,720) (1,939)
Currency in USD.
maybe
are you cool enough for OTC
we sing it
ala Taio Cruz feat. Kylie M. HIGHER
that´s right
i´m now on bid 0,70/ 8000
good morning
how it looks today
thx
i can´t see level 2
now 0,65/0,99 ?
today start 1,02 usd ?
is it good ? many numbers
that´s right da chef
we lose nothing
then we have 1$ for 1 share
big yes lmcat
there is no way for down
SNGX GO
congratulations
that´s right
i can tell you
HOLD YOUR SHARES
next year you get over 0,15 usd
nice shoot
BAM Capital, LLC (490 000 shares) ?
let´s get it start it
go sngx
0,0014 what a joke
make it double
then you have 0,0863
that´s right subgrabber
and we have time enough
wait and see for better times
pipeline = clear
cash = clear
now = work
I wish we all a lot succeed
the wrangling around the shares will soon go off
be cool
i´ve over 900k
i would buy all i can get
for 3 cent "oh sorry i mean" for nothing